ceo still getting paid over $1 million annum
you sure oil companies have underperformed clsn ?
I would not think that here is a scarcity of patients suffering from primary liver cancer. Still it takes forever to enroll these poor souls.
On July 14 and July 15, 896,600 and 3,076,000 shares of CLSN were traded, respectively. I'm curious the effect of these trades on institutional holdings. We won't know until the 9/30/15 numbers are reported.
1. FRIGATE VENTURES LP 1,083,864
2. BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A. 982,475
3. SABBY MANAGEMENT, LLC 633,396
4. VANGUARD GROUP INC 576,774
5. ROYCE & ASSOCIATES LLC 213,159
If you're long it doesn't matter. It just give everyone a good opportunity to accumulate. There are plenty of great things to come.
Sentiment: Strong Buy
All for show. It's like hitting a guy when he's down -- and right now, CLSN is down. I thought that it was a pretty good week and a half as far as results, but there is no buying interest right now. I'm not certain what will change that around in the near term.
Mad, you've been around quite a while. My belief has been steady, bypassing ph2 was the kiss of death, which I believe would have addressed and probably have adjusted trial protocol for continuation to a ph3. The Co. & FDA allowed a short sheet to ph3 that missed data that I believe would have been discovered in ph2. Ampo, however, post-hoc is playing out that way. Imo, the miss on ph2 was devastating to where the CO.'s integrity as as an investment stands today.
clsn rose from $4 to $9 in 2012 after I started warning of phase III failure. then in a split second, I was vindicated and wealthier on jan 31, 2013, when clsn plunged from $8s to $1s. that was pre split, adjusted $8 was $36 today. AF reports cant be ignored, spot on accuracy when it comes to clsn. I have cited his comments often in trying to help warn others to not be ostriches
getting approved in usa will take years, what justifies significant valuation. clsn will continuously run short on cash and do many more fundraisers. investors in clsn don't get it when it comes to impact on share price when companies D I L U T E. one could strongly argue the practice of paying huge salaries without revenues, covering those salaries by constantly doing fundraisers is a legalized ponzi scheme. I don't respect this business practice, nor pump dude who wont discuss it and they pretend it isn't happening.
I don't drove the price of clsn. leadership, phase III failure, no revenues, high cash burn rate, reverse splits, and constant D I L U T I O N have driven the price into the ground.
Hardly a new account. I was posting on here when Chueng was in charge. Why don't you actually address the points I raised. Dumber ffffffffffff
STS isn't driving the price of CLSN down, he is not the enemy. The fact that his posts bother you so much indicates that you are afraid that he is correct. This share price will not gain traction until there is actual quantifiable success, meaning approval for which a dollar value market can be estimated. This company has too great of a history of failure for it to be otherwise. The HEAT trial was fatally flawed from the beginning. The dosage was controlled by the protocol but that was not enough. No matter the concentration of t'dox in the bloodstream, enough blood needed to flow through the heated zone to release an efficacious amount of t'dox to the tumor. The amount of blood flow would be effected by location, heart rate, and most important by time. The trial protocol did not control time of heating at all. This was a fatal oversight and the surprise registered by MT and NB at the announcement of the outcome made it plain that they had not considered this important variable.
It's fast tracked. The largest market is in Japan due to Hep A anyway. Primary liver cancer and liver metastasis just got added to their EAP through myTomorrows along with recurrent chest wall cancer because of the current results of their phase III trail.You're lost boy. Wrong short position to play with.
Sentiment: Strong Buy
The Heat Trial was a success, got them the early access in EU for liver cancer.
Lets see what happens with the liver indication with China later this year.